July 23, 2009
MOUNTAIN VIEW, Calif.
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of system solutions to acute healthcare facilities, today announced results for its second quarter ended June 30, 2009.
GAAP results: Revenue for the second quarter of 2009 was $52.6 million, up $0.4 million or 0.8% from the first quarter of 2009, and down $10.7 million or 16.9% from the second quarter of 2008.
Second quarter 2009 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $0.9 million, or $0.03 per diluted share. This compares to net loss of $1.9 million, or ($0.06) per diluted share in the first quarter of 2009 and net income of $2.8 million, or $0.08 per diluted share in the second quarter of 2008.
Non-GAAP results: Excluding the impact on our results of recording $2.4 million in share-based compensation expense related to SFAS No. 123R, non-GAAP net income was $3.3 million for the second quarter of 2009, or $0.10 per diluted share. This compares to non-GAAP net income of $2.1 million, or $0.07 per diluted share for the first quarter of 2009, which as well as excluding $2.5 million in stock compensation expense, also excludes a charge of $1.5 million (net of tax) relating to a reduction in force. Second quarter 2009 results compare to non-GAAP net income of $5.7 million, or $0.17 per diluted share for the second quarter of 2008.
“I am pleased with our performance in Q2 2009," said Randall Lipps, Omnicell President, Chairman and CEO. "We continuously hear from our customers that our medication and supply automation solutions are enabling physicians and nurses to spend more time delivering care, rather than time consuming manual processes. Our solutions continue to attract new customers who are committed to having the safest and most effective automation capabilities in their hospitals.”
Read entire article.
Rob Seim, Chief Financial Officer, Omnicell, Inc.
1201 Charleston Road, Mountain View, CA 94043
800-850-6664, ext. 6478